LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF7 | A443654 | 3.33 | uM | LJP6 | 72 | hr | 1389 | 803 | 5667 | 0.1418 | -0.1368 |
MCF7 | OSI-027 | 3.33 | uM | LJP6 | 72 | hr | 1389 | 2141 | 5667 | 0.3779 | 0.1759 |
MCF7 | XMD11-85h | 3.33 | uM | LJP6 | 72 | hr | 1389 | 4145 | 5667 | 0.7313 | 0.6441 |
MCF7 | HG-6-64-01 | 3.33 | uM | LJP6 | 72 | hr | 1389 | 3449 | 5667 | 0.6086 | 0.4815 |
MCF7 | WH-4-025 | 3.33 | uM | LJP5 | 72 | hr | 1389 | 1662 | 5667 | 0.2933 | 0.0639 |
MCF7 | WZ-4-145 | 3.33 | uM | LJP6 | 72 | hr | 1389 | 2662 | 5667 | 0.4697 | 0.2976 |
MCF7 | XMD16-144 | 3.33 | uM | LJP5 | 72 | hr | 1389 | 1860 | 5667 | 0.3282 | 0.1101 |
MCF7 | Brivanib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 5732 | 5667 | 1.0114 | 1.0151 |
MCF7 | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 890 | 5667 | 0.1570 | -0.1166 |
MCF7 | BX-912 | 3.33 | uM | LJP5 | 72 | hr | 1389 | 2637 | 5667 | 0.4653 | 0.2918 |
MCF7 | Canertinib | 3.33 | uM | LJP6 | 72 | hr | 1389 | 3496 | 5667 | 0.6168 | 0.4924 |
MCF7 | Celastrol | 3.33 | uM | LJP6 | 72 | hr | 1389 | 1322 | 5667 | 0.2333 | -0.0156 |
MCF7 | CGP60474 | 3.33 | uM | LJP5 | 72 | hr | 1389 | 359 | 5667 | 0.0634 | -0.2406 |
MCF7 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 1389 | 434 | 5667 | 0.0766 | -0.2232 |
MCF7 | CHIR-99021 | 3.33 | uM | LJP6 | 72 | hr | 1389 | 3384 | 5667 | 0.5971 | 0.4663 |
MCF7 | CP724714 | 3.33 | uM | LJP5 | 72 | hr | 1389 | 5059 | 5667 | 0.8927 | 0.8578 |
MCF7 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 1389 | 5916 | 5667 | 1.0439 | 1.0581 |
MCF7 | Crizotinib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 1744 | 5667 | 0.3078 | 0.0831 |
MCF7 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 3516 | 5667 | 0.6204 | 0.4972 |
MCF7 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 1011 | 5667 | 0.1784 | -0.0884 |
MCF7 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 1389 | 1046 | 5667 | 0.1847 | -0.0800 |
MCF7 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 3455 | 5667 | 0.6096 | 0.4828 |
MCF7 | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 1389 | 6070 | 5667 | 1.0710 | 1.0941 |
MCF7 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 6425 | 5667 | 1.1336 | 1.1769 |
MCF7 | Foretinib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 1375 | 5667 | 0.2427 | -0.0032 |